Xolatryp Enhances Anthracycline Anti-Tumour Efficacy
Open PDF
| Stock | Nyrada Inc (NYR.ASX) |
|---|---|
| Release Time | 20 May 2026, 9:13 a.m. |
| Price Sensitive | Yes |
This feature provides summaries of price-sensitive announcements for companies followed by users on InvestorPA.
The summaries are generated by large language models so please interpret with care.
Nyrada Announces Positive Results for Xolatryp in Liver Cancer Study
Key Points
- Xolatryp shows significant anti-tumour activity in liver cancer model
- Combination with doxorubicin shows enhanced efficacy
- Patent application filed for Xolatryp as anti-cancer agent
Full Summary
Nyrada Inc. announced that its lead drug candidate, Xolatryp, demonstrated clear anti-tumour activity in a preclinical model of liver cancer. The study showed that Xolatryp, both as a monotherapy and in combination with doxorubicin, significantly reduced tumour volume. The combination treatment exhibited the greatest reduction in tumour volume and was well tolerated. A provisional patent application for Xolatryp as an anti-cancer agent has been lodged.
Outlook
Nyrada plans to further evaluate Xolatryp across additional tumour types and in combination with other anti-cancer agents.
Sign in to get more information about the company, including guidance changes and other insights.
Sign In